Introduction
Mitochondria are vital for cells especially that have constant high-energy demands, like muscle and brain cells. Several disorders can result from mitochondrial dysfunction. The prototypic mitochondrial diseases are Leber hereditary optic neuropathy (LHON), myoclonus epilepsy with ragged red fibers, and mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS). 1 Mitochondrial DNA (mtDNA) mutations may also confer risk for common polygenic diseases, such as Parkinson disease, Alzheimer disease, and bipolar disorder. [2] [3] [4] [5] [6] Direct and indirect lines of evidence suggest mitochondrial pathology in schizophrenia (SZ). SZ shares several features with mtDNA disorders, such as pathogenesis in the brain and variable severity. Some case studies have documented SZ and other psychotic disorders in patients exhibiting MELAS. [7] [8] [9] Earlier studies of postmortem SZ brains revealed altered gene expression in the mitochondrial oxidative phosphorylation pathway. 10, 11 There is additional evidence from postmortem brain studies for oxidative stress-induced cellular damage. 12 This damage can be attributed to mitochondrial dysfunction because mitochondria are major sites for the reactive oxygen species generation. 13, 14 Previous studies have also suggested that mtDNA variants may be associated with SZ. Munakata et al 15 suggested a role for the mt.tRNA3243A>G mutation in the etiology of SZ. 15 Marchbanks et al 16 reported heteroplasmic mt.12027T>C variation in the ND4 gene in postmortem brain samples from SZ patients. 16 Recently, Martorell et al 17 identified 2 nonsynonymous variants in the ND5 gene in a SZ patient. These variants were previously described among bipolar disorder patients.
ND4 and ND5 (NCBI Gene ID 4540) are mitochondrial genes encoding complex I components involved in oxidative phosphorylation process. Hence, these studies are consistent with recent gene expression data from postmortem SZ samples. 11 In order to assess the contribution of mtDNA variations to SZ genesis, we analyzed mtDNA sequence data. We initially investigated pooled DNA samples from cases and controls, followed by individual sequencing among 2 sets of cases and controls.
Methods

Participants
Two sets of nonoverlapping cases and controls were studied (see table 1 ). Samples from set 1 were used for the initial analyses, including the pooled assays. Samples from set 2 were used for further detailed analysis.
Set 1-Cases. Consenting patients of Caucasian ancestry with schizophrenia or schizoaffective disorder (SZ/SZA, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition [DSM-IV], criteria) were included for pooled DNA analysis (n = 180). Of these, DNA from 166 cases was later sequenced individually (table 1) . Details about their ascertainment and diagnosis are described elsewhere.
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Set 1-Controls. Cord blood samples from live births at local hospital were used as community-based controls (n = 180). All the samples had Caucasian ancestry, based on maternal report. No information other than ethnicity and gender was available about these samples.
Set 2-Cases. An independent sample of 244 additional SZ/SZA patients (DSM-IV criteria) of Caucasian ancestry were ascertained and diagnosed using the same procedures as the patients in set 1.
Set 2-Controls. Adult Caucasian controls (199 men and 213 women) from Southwestern Pennsylvania (principally Allegheny County) enrolled in the University of Pittsburgh, Adult Health and Behavior project, were included. Participation was restricted to the individuals without a history of myocardial infarction or cancer treatment within the preceding year; chronic kidney or liver disease; diabetes requiring insulin therapy; and major neurological disorders or psychotic illness, use of psychotropic, glucocorticoid, or weight-loss medications, and, in women, pregnancy (data collected between 2001 and 2005). In addition, 96 Caucasian adults screened for absence of alcohol/illicit substance abuse were included from another study. 20 None of these individuals reported a history of psychosis.
Written informed consent was obtained from all the participants, except neonatal controls, in accordance with University of Pittsburgh Institutional Review Board guidelines.
DNA Extraction and Preparation of Pools
DNA was extracted from venous blood using the phenolchloroform method and quantified using the PicoGreen dsDNA quantitation method as described by the manufacturer http://probes.invitrogen.com/media/pis/ mp07581.pdf.
Pools of genomic DNA were prepared separately for cases and controls as described. 21 Each pool included 180 samples (cases or controls).
Polymerase Chain Reaction
We amplified and sequenced mtDNA in each pool using 38 overlapping amplicons. The ND5 gene was screened using 5 pairs of overlapping amplicons. All the primers were designed using the mtDNA sequence from human mitochondrial genome database 22 and compared with genomic DNA sequences using NCBI BLAST to ensure specific amplification of regions of the mitochondrial genome (primer list provided in Supplementary Tables S1 and S2). Polymerase chain reactions (PCRs) (10 ll) included 5 pmol primers, 200 lM dNTP, 1.5 mM MgCl 2 , 0.5 U AmpliTaq Polymerase (PE Biosystems, Foster City, CA), 13 buffer, and genomic DNA (60 ng). PCR cycles comprised initial denaturation at 94°C for 3 minutes, followed by 35 amplification cycles (94°C for 30 seconds, 60°C for 30 seconds, and 72°C for 60 seconds), and final extension-72°C for 7 minutes, followed by storage at 4°C till further use. The amplified products were checked on 2.0% agarose gels using ethidium bromide staining.
Pooled DNA Sequencing and Individual Sequencing
Amplified PCR products were treated with ExoSAP-IT (USB, Cleveland, OH) at 37°C for 15 minutes followed by enzyme denaturation at 80°C for 15 minutes, and storage Age not calculated because the samples were composed of DNA extracted from neonatal cord blood samples. The samples from set 1 were also used for pooled DNA analysis.
at 4°C. Treated PCR products were sequenced with appropriate primers and BigDye terminator V3.0 cycle sequencing reagents (Applied Biosystems, Foster City, CA) using the following conditions: 95°C for 30-second initial denaturation and 25 cycles of 95°C for 15 seconds, 50°C for 15 seconds, and 60°C for 4 minutes. Sequencing reactions were isopropanol precipitated and analyzed on an ABI PRISM 3700 DNA Analyzer (Applied Biosystems). Sequencing traces were analyzed using SEQUENCHER software (GeneCodes Corporation, Ann Arbor, MI). All sequencing traces were visually examined to ascertain base calls made by software. Each amplicon was sequenced in triplicate for both case and control pools. Sequencing traces were checked and confirmed by 2 investigators. All sequences and observed mtDNA variations were individually compared with the human mitochondrial genome database.
22,23
For pooled DNA sequencing, peak heights of the sequencing traces were used to estimate allele frequencies using ABI PRISM sequencing analysis software version 3.7.
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Total Mutation Load/Expressed Mutation Load
The total mutation load was calculated as the number of DNA variations observed per base screened in the respective group. The expressed mutation load is defined as the number of variations causing changes in the amino acid sequence, as a fraction of the number of bases sequenced in that group. Note: Mutation load: (total number of variations observed in each group)/(total number of bases analyzed for all samples in that group). Numbers of bases not covered in set 2 were considered while calculating mutation loads for set 2 samples. Individual sequencing of the ND5 gene in cases and controls from both the sets. The frequency of subjects showing variations did not vary significantly between cases and controls in both sets. Some subjects in each group had more than one variation and or both synonymous and nonsynonymous variations (set 1 cases, n = 64; neonatal controls, n = 57; set 2 cases, n = 105, and adult controls, n = 114). The total and expressed mutation loads are representing frequencies of total number of variations and nonsynonymous variations with in that group. a Some samples had more than one variant.
Statistical Analysis
We employed an R script console (version 1.9.1) to compare the differences in allele frequencies between cases and controls for pooled DNA sequencing as described by Chowdari et al. 21 A nonparametric Mann-Whitney test was used to compare the distribution of mtDNA variations between cases and controls, and power calculations were carried out based on the samples available in set 2 (SAS, version 9.1).
Results
Pooled DNA Sequencing Using Cases and Neonatal Cord Samples From Set 1
We observed 44 common polymorphisms. The list of polymorphisms is available in Supplementary Table   S3 . All these polymorphisms have been reported in public databases. 22, 23, 25, 26 Two variations in the ND5 gene showed significant case-control differences with regard to minor allele frequencies using the R script analysis (mt.13368G/A, cases: 29.5%, controls: 18.5%, Z score = 2.33, P = 0.019; mt.13708G/A (ND5: 458Ala / Thr), cases: 13.7%, controls: 7.1%, Z score = 2.02, P = 0.043, see figure 1 ).
These suggestive findings prompted us to sequence the ND5 gene individually among cases and controls from set 1.
Individual Sequencing of ND5 Gene in Cases and Controls Set 1. We confirmed the mt.13368G/A and mt.13708A/ G (ND5: 458Ala / Thr) variations in individual sequencing traces, initially observed by pooled DNA sequencing (mt.13368G/A, cases: 12/166 and controls: 11/174; mt.13708A/G (ND5: 458Ala / Thr), cases: 14/ 166 and controls: 16/174). However, the case-control differences for these variants were not statistically significant. Though all samples comprising the DNA pools were sequenced individually, satisfactory sequencing traces could not be obtained from some samples (cases, n = 14; controls, n = 6). These traces were not used for case-control comparisons, and details for these individuals are not reported in table 1.
One or more mtDNA variant was present among 105 cases and 109 controls. The proportion of cases (63.2%) with variations was not significantly different compared with controls (62.6%, see table 2). A total of 92 cases (55.4%) had synonymous and 54 cases (32.5%) had nonsynonymous variations. In comparison, 100 controls (57.5%) with synonymous and 54 controls with nonsynonymous (31.0%) variations were observed.
We observed a total of 71 synonymous and 33 nonsynonymous variants in set 1 (listed in Supplementary Table S4 ). Some of these variations were restricted to either cases (synonymous: n = 38, nonsynonymous: n = 14) or to controls (synonymous: n = 13, nonsynonymous: n = 6). These proportions are not significantly different.
The total mutation load was marginally higher among the cases (0.70 3 
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À3 per base), compared with the controls (0.59 3 
À3 per base, table 2). The expressed mutation load was also not significantly different between the case and control groups for (0.19 3 
À3 per base, for each group, table 2).
ND5 Gene Sequence Analysis for Set 2 Participants
Though the results from the pooled DNA analyses could not be confirmed by the individual sequencing, the presence of large numbers of other variants in the ND5 gene led us to investigate a second, larger, independent sample that included adult control individuals. We successfully sequenced approximately 90% of the ND5 gene sequence, individually in all cases and controls from set 2. However, 2 small regions of the ND5 gene (mt.12741 to mt.12941 and mt.13552 to mt.13634) could not be sequenced satisfactorily in any of the samples.
The cases and the screened adult controls showed nominal differences in the number of individuals with variants (cases = 68.0%, controls = 62.2%, P = 0.014; for synonymous variations, Z score = 2.236, P = 0.021 and for nonsynonymous variations, Z score = 1.323, P = 0.191).
In set 2, we observed 129 synonymous and 62 nonsynonymous mtDNA variations (see Supplementary Table  S4) . A total of 76 variations (56 synonymous and 20 nonsynonymous) overlapped with the variations observed in set 1. The cases had 63 synonymous and 42 nonsynonymous variations. We detected 97 synonymous and 45 nonsynonymous variations among the controls. There were 17 nonsynonymous variations restricted to the cases and 32 synonymous variations observed exclusively among the cases. There were 20 nonsynonymous and 66 synonymous variations that were present only among the controls.
The total mutation load was marginally higher among the cases (0.94 3 
10
À3 per base), compared with the controls (0.71 3 
À3 per base) (table 2) . The expressed mutation load was not significantly different among cases (0.27 3 
À3 per base) and controls (0.20 3 10 À3 per base) (table 2).
Analysis of Combined Samples
We identified a total of 219 variations among cases and controls from both sets (see Supplementary Table S4 ). From both sets 1 and 2, we identified 13 synonymous and 11 nonsynonymous novel variations in the ND5 gene not reported in the mitochondrial database. 22, 23, 25, 26 Of these 24 novel variations, 7 synonymous and 6 nonsynonymous variations were restricted to the cases.
Two nonsynonymous variations (mt.13129C / T, ND5: 265Pro / Ser and mt.14059A / G, ND5: 575Ile / Val) were restricted to controls and cases, respectively. Each of these variants was present in 5 or more subjects in each group. The proportions of controls showing variations were not different between set 1 and set 2 (set 1, overall: 62.6%, nonsynonymous: 31.0%, synonymous: 57.4% and set 2, overall: 62.1%, nonsynonymous: 26.5%, synonymous: 54.1%).
Power Analysis
In both sets of samples, the proportion of participants with variants was approximately 65%. If we consider only our set 2 samples (244 cases, 508 controls), we estimate that we had 73.8% power to detect a 10% difference in the proportion of individuals with variants between groups and 23.8% power to detect a 5% difference between groups (alpha threshold of 0.05 for both estimates).
Polymorphisms Related to Haplogroups
The Caucasian population can be classified into 9 main haplogroups, namely H, I, J, K, T, U, V, W, and X, based on polymorphic mtDNA variants. 27, 28 Two of these markers (mt13366 BamHIand mt13704 BstNI), associated with haplogroups T and I, respectively, were present in the ND5 gene. The frequencies of these markers were not different between cases and controls (mt.13366 BamHI, cases: 8.3% and controls: 6.9%; mt.13704 BstNI, cases: 8.5% and controls: 10.1%).
Inheritance Patterns
DNA was available from mothers and affected siblings of 10 cases who had mtDNA variants, enabling us to evaluate maternal inheritance for these variants. Maternal inheritance of mtDNA variations was observed in all these cases. The sequencing traces for one such family is shown in figure 2A . In this family, the mother and the affected sibling shared the mt.13924C / T(ND5: 530Pro / Ser). In another family, the proband had heteroplasmy for mt.14131A/C (ND5: 599Leu/Met), which was present in the mother (figure 2B). DNA was available from the affected siblings for 2 cases. We observed maternal inheritance for 2 nonsynonymous mtDNA variations in the first pair of affected siblings [mt.13924C / T(ND5: 530Pro / Ser) ( figure 2A ) and mt.14059A / G(ND5: 575Ile / Val)]. In the second pair, 2 nonsynonymous variations [mt.12940G / A(ND5: 202Ala / Thr) and mt.13879T / A(ND5: 515Ser / Thr)] were maternally inherited (data not shown).
Discussion
Our aim was to identify mtDNA variations that may be associated with SZ. Initially, we analyzed the entire mitochondrial genome among cases and controls, using the pooled DNA sequencing method. Pooled DNA sequence analysis enables rapid identification of common polymorphisms. 21, 29 We identified 44 common polymorphisms, all of which have been reported in public databases. 22, 23 The frequency of one ND5 polymorphism (mt.13704 BstNI: 9.1%) used for haplogroup definition is consistent between our samples and published data. 27 Following pooled sequencing, we observed a significant case-control difference for 2 variants in the ND5 gene. We followed up this result by comprehensively sequencing the ND5 gene in all subjects. We confirmed the presence of homoplasmic variations at both positions showing case-control differences in the pooled analyses, but the significant allele frequency difference observed in the pooled DNA analysis was not reflected in the analyses of individual traces. These results are consistent with similar disparities noted in a recent whole-genome association study of bipolar disorder, in which results from pooling were also not confirmed by individual genotyping. 30 There are certain limitations to the pooling strategies. Peak heights generated in the pooled DNA sequencing traces may not indicate allele frequencies accurately due to the differential amplification of alleles during PCR. 21, 31 These workers have emphasized the necessity of applying correction factors generated by sequencing small number of heterozygotes for the estimation of allele frequency measurements. With genomic DNA, it is feasible to obtain precise correction factors using individuals with heterozygous genotypes. The precision arises from the fact that the heterozygous have equal number of chromosomes with each allele. Such precision is not possible when studying mtDNA because the number of mtDNA copies with the mutation is unknown among individuals with heteroplasmy. It is also possible that the ratio of mtDNA to nuclear DNA in the blood cells might vary among individuals. These issues may explain the significant difference of allele frequencies observed in our pooled DNA sequencing compared with individual sequencing.
Intriguingly, we also observed an unexpectedly large number of ND5 variations among our subjects following individual sequence analyses. Our observations are consistent with a prior study that suggested the ND5 gene as a mitochondrial mutation hot spot. 32 Most of the variants observed in our study have been reported elsewhere and thus are unlikely to be sequencing artifacts. 22, 23, 25, 26 The unusual diversity is consistent with the relatively high mutation rates known to occur in mtDNA. These rates have been cited in favor of mtDNA being a risk factor for SZ. 33 However, the total number of variations as well as the frequency of nonsynonymous and synonymous variations was not significantly different between cases and controls in the first set. Nominally significant differences were noted in the second set, suggesting a need for evaluations using even larger samples. We analyzed unscreened neonatal controls in our first set of samples. Population stratification and the possibility that some of the controls might be diagnosed with SZ in adulthood could confound our results. Because the lifetime prevalence of SZ is approximately 1%, there is negligible loss of power when you consider these unscreened neonatal controls. 34 Our power analyses suggested the samples used here had reasonable power to detect a modest or large effect size but relatively poor power if the expected effect sizes were small.
Earlier studies have reported on ND5 gene variations associated with prototypic mitochondrial disorders and other neurological/neuropsychiatric disorders. Parker and Parks 5 observed differential expression of the ND5 gene variants among subjects with Parkinson disease. These ND5 variations were also previously associated with severe neurological damage in disorders like Leigh disease and MELAS. 35, 36 In a recent study, Zhadanov et al 37 reported a de novo ND5 gene mutation associated with Leigh syndrome cases. They suggested a lethal effect of the ND5 gene mutation on the structure and function of the mitochondrial complex 1. Vanniarajan et al 32 identified a novel nonsynonymous variation in the ND5 gene (mt.13565C / A, ND5: 410Ser / Tyr) that has been implicated in late-onset MELAS. We also identified variations in the ND5 gene that have been reported in several disorders, including LHON, MELAS, idiopathic Parkinson disorder, and bipolar disorder. We are uncertain of the functional implications for these rare variations in our subjects.
Recently, Martorell et al 17 reported a SZ case with specific nonsynonymous variations in the ND5 gene (mt.12403C / T, ND5: 23Leu / Phe and mt.12950A / C, ND5: 205Asn / Thr). Both variations were present in the same proband (cases: 1/6, controls: 0/95) in their samples. These 2 variations were also described among bipolar disorder patients. 18 We observed mt.12403C / T (ND5: 23Leu / Phe) in 2 of our adult controls but did not detect them in any of our cases. Interestingly, both adult controls with mt.12403C / T (ND5: 23Leu / Phe) also had mt.12950A / C, similar to Martorell et al. 17 Only one of our cases had the mt.12950A / C (ND5: 205Asn / Thr) variation. Martorell et al 17 also identified another variation (synonymous, mt.12705C / T) present in one of their probands but none of their controls. In our study, mt.12705C / T was identified among 36 cases and 79 controls. This dissimilarity could be due to the difference in sample numbers between these 2 studies.
Samples from available family members enabled us to ascertain the inheritance of variants identified among 10 cases. DNA was available from the proband, the mother, and an affected sibling in 2 families. All the affected individuals showed maternal inheritance for the observed ND5 variations, suggesting that the variants are not due to somatic mutations in these cases. Additional comprehensive screening of the entire mtDNA in individual cases and controls, along with their first-degree relatives, can help in ascertaining somatic versus germ-line origin for the other mtDNA variations.
In conclusion, our studies do not support associations between ND5 gene variations and SZ. However, we observed several variants among our patients that have also been reported in other mtDNA disorders. Thus, our result warrants further investigations of the ND5 gene association in larger sample. Also the functional impact of such variants and their relationship to SZ needs to be explored.
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